
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions β written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Secondary amyloidosis natural history, complications and prognosis
Introduction
Overview
Overview
In amyloidosis, insoluble fibrils of amyloid are deposited in organs, causing organ dysfunction and eventually death. Patients with amyloidosis may eventually suffer from heart failure, nephrotic syndrome, hepatomegaly and peripheral neuropathy. Prognosis is poor and 5-years survival rate is 51.3%.Infection and renal failure are the most common cause of death.
Natural History, Complications, and Prognosis
Natural History, Complications, and Prognosis
Natural History
- In amyloidosis, insoluble fibrils of amyloid are deposited in the organs, causing organ dysfunction.[1]
- Patients with amyloidosis may eventually suffer from nephrotic syndrome, renal failure, and death.
Complications
- In patients with amyloidosis, the most frequent complications include:[2]
- Nephrotic syndrome, the most common
- Hepatomegaly
- Peripheral neuropathyΒ
- Heart failure
Prognosis
- Prognosis is poor and 5-years survival rate is 51.3%.[3]
- Following factors are associated with higher rates of mortality:
- It has been reported that, survival rate is not affected by the underlying etiology.[4]
- Infection and renal failure are the most common cause of death.
- Median survival has been reported between 6 to 9 years.[1]
- The most important predictable factor for development of renal failure and death is higher production of SAA.
References
References
- β 1.0 1.1 Lachmann, Helen J.; Goodman, Hugh J.B.; Gilbertson, Janet A.; Gallimore, J. Ruth; Sabin, Caroline A.; Gillmore, Julian D.; Hawkins, Philip N. (2007). “Natural History and Outcome in Systemic AA Amyloidosis”. New England Journal of Medicine. 356 (23): 2361β2371. doi:10.1056/NEJMoa070265. ISSNΒ 0028-4793.
- β Jerzykowska S, Cymerys M, Gil LA, Balcerzak A, Pupek-Musialik D, Komarnicki MA (2014). “Primary systemic amyloidosis as a real diagnostic challenge – case study”. Cent Eur J Immunol. 39 (1): 61β6. doi:10.5114/ceji.2014.42126. PMCΒ 4439975. PMIDΒ 26155101.
- β Ahbap E, Kara E, Sahutoglu T, Basturk T, Koc Y, Sakaci T, Sevinc M, Akgol C, Ucar ZA, Kayalar AO, Bayraktar F, Ozagari AA, Unsal A (July 2014). “Outcome of 121 patients with renal amyloid a amyloidosis”. J Res Med Sci. 19 (7): 644β9. PMCΒ 4214024. PMIDΒ 25364365.
- β Ayar Y, Ersoy A, Oksuz MF, Ocakoglu G, Vuruskan BA, Yildiz A, Isiktas E, Oruc A, Celikci S, Arslan I, Sahin AB, GΓΌllΓΌlΓΌ M (2017). “Clinical outcomes and survival in AA amyloidosis patients”. Rev Bras Reumatol Engl Ed. 57 (6): 535β544. doi:10.1016/j.rbre.2017.02.002. PMIDΒ 29173691.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] Associate Editor(s)-in-Chief: Shaghayegh Habibi, M.D.[2] Sahar Memar Montazerin, M.D.[3]
